Prenatal lead levels, plasma amyloid β levels, and gene expression in young adulthood

Environmental Health Perspectives

Volumn 120, Issue 5, 2012, Pages 702-707

  Mazumdar, Maitreyi ^a,b   Xia, Weiming ^c   Hofmann, Oliver ^b   Gregas, Matthew ^a   Sui, Shannan Ho ^b   Hide, Winston ^b   Yang, Ting ^c   Needleman, Herbert L ^d   Bellinger, David C ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Children; Fetal basis of adult disease; Human; Lead

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN [1-40]; AMYLOID BETA PROTEIN [1-42]; LEAD; UNCLASSIFIED DRUG;

ADAM METALLOPEPTIDASE DOMAIN 9 GENE; ADULT; ADULTHOOD; ALZHEIMER DISEASE; ARTICLE; BLOOD ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GENE; GENE EXPRESSION; HUMAN; LEAD BLOOD LEVEL; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN ASSOCIATED PROTEIN 1 GENE; MALE; MICROARRAY ANALYSIS; NEUROTOXICITY; PRENATAL EXPOSURE; PRIORITY JOURNAL; QUESTIONNAIRE; RETICULON 4 GENE;

ANIMALIA;

EID: 84861018468     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.1104474     Document Type: Article

References (53)

1. Abdullah L, Paris D, Luis C, Quadros A, Parrish J, Valdes L, et al. 2007. The influence of diagnosis, intra- and inter-person variability on serum and plasma Abeta levels. Neurosci Lett 428:53-58.
2. Allinson TM, Parkin ET, Turner AJ, Hooper NM. 2003. ADAMs family members as amyloid precursor protein α-secretases. J Neurosci Res 74:342-352.
3. Barker DJ. 1995. Fetal origins of coronary heart disease. BMJ 311:171-174.
4. Barker DJ, Osmond C. 1986. Infant mortality, childhood nutrition, and ischaemic heart disease in England and Wales. Lancet 1:1077-1081.
5. Basha MR, Wei W, Bakheet SA, Benitez N, Siddiqi HK, Ge YW, et al. 2005. The fetal basis of amyloidogenesis: exposure to lead and latent overexpression of amyloid precursor protein and β-amyloid in the aging brain. J Neurosci 25:823-829.
6. Bellinger DC. 2004. Lead. Pediatrics 113:1016-1022.
7. Bellinger D, Leviton A, Waternaux C, Needleman H, Rabinowitz M. 1987. Longitudinal analyses of prenatal and postnatal lead exposure and early cognitive development. N Engl J Med 316:1037-1043.
8. Bellinger D, Sloman J, Leviton A, Rabinowitz M, Needleman HL, Waternaux C. 1991. Low-level lead exposure and children's cognitive function in the preschool years. Pediatrics 87:219-227.
9. Bellinger DC, Stiles KM, Needleman HL. 1992. Low-level lead exposure, intelligence and academic achievement: a long-term follow-up study. Pediatrics 90:855-861.
10. Buerger K, Frisoni G, Uspenskaya O, Ewers M, Zetterberg H, Geroldi C, et al. 2009. Validation of Alzheimer's disease CSF and plasma biological markers: the multicentre reliability study of the pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI). Exp Gerontol 44:579-585.
11. Cobb JL, Wolf PA, Au R, White R, D'Agostino RB. 1995. The effect of education on the incidence of dementia and Alzheimer's disease in the Framingham Study. Neurology 45:1707-1712.
12. Cong L, Jia J. 2011. Promoter polymorphisms which regulate ADAM9 transcription are protective against sporadic Alzheimer's disease. Neurobiol Aging 32:54-62.
13. Cosentino SA, Stern Y, Sokolov E, Scarmeas N, Manly JJ, Tang MX, et al. 2010. Plasma β-amyloid and cognitive decline. Arch Neurol 67:1485-1490.
14. Deuss M, Reiss K, Hartmann D. 2008. Part-time α-secretases: the functional biology of ADAM 9, 10 and 17. Curr Alzheimer Res 5:187-201.
15. Fukumoto H, Tennis M, Locascio JJ, Hyman BT, Growdon JH, Irizarry MC. 2003. Age but not diagnosis is the main predictor of plasma amyloid β-protein levels. Arch Neurol 60:958-964.
16. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, et al. 2004. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5:R80; doi:10.1186/gb-2004-5-10-r80 [Online 15 September 2004].
17. Giedraitis V, Sundelof J, Irizarry MC, Garevik N, Hyman BT, Wahlund LO, et al. 2007. The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer's disease. Neurosci Lett 427:127-131.
18. Gu H, Wei X, Monnot AD, Fontanilla CV, Behl M, Farlow MR, et al. 2011. Lead exposure increases levels of β-amyloid in the brain and CSF and inhibits LRP1 expression in APP transgenic mice. Neurosci Lett 490:16-20.
19. Hardy J, Selkoe DJ. 2002. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297:353-356.
20. He W, Lu Y, Qahwash I, Hu XY, Chang A, Yan R. 2004. Reticulon family members modulate BACE1 activity and amyloid-β peptide generation. Nat Med 10:959-965.
21. Hess K, Straub PW. 1974. Chronische Bleivergiftung (Chronic lead poisoning) [in German]. Schweiz Rundsch Med Prax 63:177-183.
22. Huang H, Bihaqi SW, Cui L, Zawia NH. 2011. In vitro Pb exposure disturbs the balance between Aβ production and elimination: the role of AβPP and neprilysin. Neurotoxicology 32:300-306.
23. Hyman BT, Strickland D, Rebeck GW. 2000. Role of the low-density lipoprotein receptor-related protein in β-amyloid metabolism and Alzheimer disease. Arch Neurol 57:646-650.
24. Ioannidis JP. 2005. Why most published research findings are false. PLoS Med 2: e124; doi:10.1371/journal.pmed.0020124 [Online 30 August 2005].
25. Joseph KS, Kramer MS. 1996. Review of the evidence on fetal and early childhood antecedents of adult chronic disease. Epidemiol Rev 18:158-174.
26. Kauffmann A, Gentleman R, Huber W. 2009. arrayQuality-Metrics-a bioconductor package for quality assessment of microarray data. Bioinformatics 25:415-416.
27. Kosaka T, Imagawa M, Seki K, Arai H, Sasaki H, Tsuji S, et al. 1997. The beta APP717 Alzheimer mutation increases the percentage of plasma amyloid-beta protein ending at A beta 42(43). Neurology 48:741-745.
28. Lanphear BP, Hornung R, Khoury J, Yolton K, Baghurst P, Bellinger DC, et al. 2005. Low-level environmental lead exposure and children's intellectual function: an international pooled analysis. Environ Health Perspect 113:894-899.
29. Lin D, Shkedy Z, Yekutieli D, Burzykowski T, Gohlmann HW, De Bondt A, et al. 2007. Testing for trends in dose-response microarray experiments: a comparison of several testing procedures, multiplicity and resampling-based inference. Stat Appl Genet Mol Biol 6:1-26.
30. MacArthur BD, Lachmann A, Lemischka IR, Ma'ayan A. 2010. GATE: software for the analysis and visualization of high-dimensional time series expression data. Bioinformatics 26:143-144.
31. Mazumdar M, Bellinger DC, Gregas M, Abanilla K, Bacic J, Needleman HL. 2011. Low-level environmental lead exposure in childhood and adult intellectual function: a follow-up study. Environ Health 10:24; doi:10.1186/1476-069X-10-24 [Online 30 March 2011].
32. Murayama KS, Kametani F, Saito S, Kume H, Akiyama H, Araki W. 2006. Reticulons RTN3 and RTN4-B/C interact with BACE1 and inhibit its ability to produce amyloid β-protein. Eur J Neurosci 24:1237-1244.
33. Needleman H. 2004. Lead poisoning. Annu Rev Med 55:209-222.
34. Niklowitz WJ. 1975. Neurofibrillary changes after acute experimental lead poisoning. Neurology 25:927-934.
35. Peterson SM, Zhang J, Weber G, Freeman JL. 2011. Global gene expression analysis reveals dynamic and developmental stage-dependent enrichment of lead-induced neurological gene alterations. Environ Health Perspect 119:615-621.
36. Sanchez L, Alvarez V, Gonzalez P, Gonzalez I, Alvarez R, Coto E. 2001. Variation in the LRP-associated protein gene (LRPAP1) is associated with late-onset Alzheimer disease. Am J Med Genet 105:76-78.
37. Schupf N, Tang MX, Fukuyama H, Manly J, Andrews H, Mehta P, et al. 2008. Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease. Proc Natl Acad Sci USA 105:14052-14057.
38. Selkoe DJ. 2008. Biochemistry and molecular biology of amyloid beta-protein and the mechanism of Alzheimer's disease. Handb Clin Neurol 89:245-260.
39. Snowdon DA, Greiner LH, Markesbery WR. 2000. Linguistic ability in early life and the neuropathology of Alzheimer's disease and cerebrovascular disease. Findings from the Nun Study. Ann N Y Acad Sci 903:34-38.
40. Sobow T, Flirski M, Kloszewska I, Liberski PP. 2005. Plasma levels of Aβ peptides are altered in amnestic mild cognitive impairment but not in sporadic Alzheimer's disease. Acta Neurobiol Exp (Wars) 65:117-124.
41. Song F, Poljak A, Valenzuela M, Mayeux R, Smythe GA, Sachdev PS. 2011. Meta-analysis of plasma amyloid-β levels in Alzheimer's disease. J Alzheimers Dis 26(2):365-375.
42. Stern Y. 2009. Cognitive reserve. Neuropsychologia 47:2015-2028.
43. Stern Y, Gurland B, Tatemichi TK, Tang MX, Wilder D, Mayeux R. 1994. Influence of education and occupation on the incidence of Alzheimer's disease. JAMA 271:1004-1010.
44. Tamaoka A, Fukushima T, Sawamura N, Ishikawa K, Oguni E, Komatsuzaki Y, et al. 1996. Amyloid β protein in plasma from patients with sporadic Alzheimer's disease. J Neurol Sci 141:65-68.
45. van Wijngaarden E, Campbell JR, Cory-Slechta DA. 2009. Bone lead levels are associated with measures of memory impairment in older adults. Neurotoxicology 30:572-580.
46. van Wijngaarden E, Winters PC, Cory-Slechta DA. 2011. Blood lead levels in relation to cognitive function in older U.S. adults. Neurotoxicology 32:110-115.
47. Warde-Farley D, Donaldson SL, Comes O, Zuberi K, Badrawi R, Chao P, et al. 2010. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res 38:W214-W220.
48. Weisskopf MG, Proctor SP, Wright RO, Schwartz J, Spiro A III, Sparrow D, et al. 2007. Cumulative lead exposure and cognitive performance among elderly men. Epidemiology 18:59-66.
49. Weisskopf MG, Wright RO, Schwartz J, Spiro A III, Sparrow D, Aro A, et al. 2004. Cumulative lead exposure and prospective change in cognition among elderly men: the VA Normative Aging Study. Am J Epidemiol 160:1184-1193.
50. Weuve J, Korrick SA, Weisskopf MG, Ryan LM, Schwartz J, Nie H, et al. 2009. Cumulative exposure to lead in relation to cognitive function in older women. Environ Health Perspect 117:574-580.
51. Wisniewski K, Jervis GA, Moretz RC, Wisniewski HM. 1979. Alzheimer neurofibrillary tangles in diseases other than senile and presenile dementia. Ann Neurol 5:288-294.
52. Wright RO, Tsaih SW, Schwartz J, Spiro A III, McDonald K, Weiss ST, et al. 2003. Lead exposure biomarkers and mini-mental status exam scores in older men. Epidemiology 14:713-718.
53. Wu J, Basha MR, Brock B, Cox DP, Cardozo-Pelaez F, McPherson CA, et al. 2008. Alzheimer's disease (AD)-like pathology in aged monkeys after infantile exposure to environmental metal lead (Pb): evidence for a developmental origin and environmental link for AD. J Neurosci 28:3-9.